PMID- 21206517
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 4
DP  - 2010 Dec 2
TI  - Improving management of patients with advanced cancer.
PG  - 415-24
LID - 10.2147/PPA.S15017 [doi]
AB  - Development of bone metastases in patients with advanced cancer is associated 
      with skeletal-related events (SREs) such as pathologic fractures, spinal cord 
      compression, the requirement for surgery or palliative radiotherapy to bone, and 
      hypercalcemia of malignancy. Skeletal morbidity may reduce patient mobility, 
      limit functional independence, and impair quality of life (QOL). Proactive 
      management of new or worsening bone pain or motor impairment is crucial because 
      of the potential for rapid progression of symptoms. Administration of 
      bisphosphonate therapy as a monthly infusion to patients with bone metastases 
      prevents or delays the onset and reduces the frequency of SREs and provides 
      clinically meaningful improvements in bone pain and QOL. In addition to 
      administration of therapy, the monthly infusion visit allows a dedicated team of 
      healthcare professionals to regularly assess SREs, response to therapy, adverse 
      events (AEs), QOL, and adherence to oral medications and supplements. The 
      continuity of care that occurs during the monthly infusion visit provides 
      oncology nurses with an opportunity to educate patients about effective 
      strategies to manage SREs and AEs. In addition, regular interaction provides 
      oncology nurses with an opportunity to recognize and proactively address subtle 
      changes in the patients' medical condition. Using a multidisciplinary medical 
      team also eliminates barriers between the various healthcare professionals 
      involved in patient management. Consequently, the monthly infusion visit can 
      result in effective patient management and improved clinical outcomes in patients 
      with malignant bone disease.
FAU - Drudge-Coates, Lawrence
AU  - Drudge-Coates L
AD  - Department of Urology, King's College Hospital, London, United Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20101202
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC3003608
OTO - NOTNLM
OT  - adverse events
OT  - bisphosphonates
OT  - bone metastases
OT  - quality of life
OT  - skeletal-related events
OT  - treatment adherence
EDAT- 2011/01/06 06:00
MHDA- 2011/01/06 06:01
PMCR- 2010/12/02
CRDT- 2011/01/06 06:00
PHST- 2010/12/01 00:00 [received]
PHST- 2011/01/06 06:00 [entrez]
PHST- 2011/01/06 06:00 [pubmed]
PHST- 2011/01/06 06:01 [medline]
PHST- 2010/12/02 00:00 [pmc-release]
AID - ppa-4-415 [pii]
AID - 10.2147/PPA.S15017 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2010 Dec 2;4:415-24. doi: 10.2147/PPA.S15017.